Clinically relevant GSK‑3β inhibitor 9‑ING‑41 is active as a single agent and in combination with other antitumor therapies in human renal cancer

Glycogen synthase kinase‑3 (GSK‑3), a serine/threonine kinase, is involved in a broad range of pathological processes including cancer. GSK‑3 has two isoforms, GSK‑3α and GSK‑3β, and GSK‑3β has been recognized as a therapeutic target for the development of new anticancer drugs. The present study aim...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International journal of molecular medicine 2020-02, Vol.45 (2), p.315-323
Hauptverfasser:	Anraku, Tsutomu, Kuroki, Hiroo, Kazama, Akira, Bilim, Vladimir, Tasaki, Masaaki, Schmitt, Daniel, Mazar, Andrew, Giles, Francis J, Ugolkov, Andrey, Tomita, Yoshihiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Apoptosis Cancer therapies Cell cycle Cell growth Cyclin-dependent kinases Cytotoxicity Gene expression Immunoglobulins Kidney cancer Kinases Laboratories Metastasis Proteins Statistical analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!